以及肝移植后代谢功能障碍相关脂肪性肝病的复发。
and recurrence of metabolic dysfunction-associated fatty liver disease after liver transplantation.
作者信息
Han Ma Ai Thanda, Olivo Raquel, Choi Catherine J, Pyrsopoulos Nikolaos
机构信息
Department of Gastroenterology and Hepatology, Rutgers New Jersey Medical School, Newark, NJ 07103, United States.
Department of Gastroenterology and Hepatology, Rutgers University, New Jersey Medical School, Newark, NJ 07103, United States.
出版信息
World J Hepatol. 2021 Dec 27;13(12):1991-2004. doi: 10.4254/wjh.v13.i12.1991.
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a new acronym adopted from the consensus of international experts. Given the increasing prevalence of MAFLD in pre-transplant settings, and recurrent graft steatosis/MAFLD are common in post-transplant settings. The impact of graft steatosis on long-term outcomes is unclear. The current knowledge of incidence rate, risk factors, diagnosis, long-term outcomes, and management of graft steatosis (both and recurrent) is discussed in this review.
代谢功能障碍相关脂肪性肝病（MAFLD）是一个从国际专家共识中采用的新首字母缩略词。鉴于MAFLD在移植前环境中的患病率不断上升，且移植后复发性移植物脂肪变性/MAFLD很常见。移植物脂肪变性对长期预后的影响尚不清楚。本综述讨论了目前关于移植物脂肪变性（原发性和复发性）的发病率、危险因素、诊断、长期预后及管理的知识。
Zotero 插件